Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

Similar articles for PubMed (Select 22516984)

1.

[Survey of tumor necrosis factor inhibitors application in patients with rheumatoid arthritis in China].

Wang XR, Su Y, An Y, Zhou YS, Zhang XY, Duan TJ, Zhu JX, Li XF, Wang CH, Wang LZ, Wang YF, Yang R, Wang GC, Lu X, Zhu P, Chen LN, Wang Y, Wang XY, Jin HT, Liu JT, Chen HY, Wei P, Wang JX, Liu XY, Sun L, Cui LF, Shu R, Liu BL, Zhang ZL, Li GT, Li ZB, Yang J, Li JF, Jia B, Zhang FX, Tao JM, Lin JY, Wei MQ, Liu XM, Ke D, Hu SX, Ye C, Han SL, Yang XY, Li H, Huang CB, Gao M, Lai P, Li XF, Song LJ, Mu R, Li ZG.

Beijing Da Xue Xue Bao. 2012 Apr 18;44(2):182-7. Chinese.

2.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

4.

Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.

Carter CT, Changolkar AK, Scott McKenzie R.

J Med Econ. 2012;15(2):332-9. doi: 10.3111/13696998.2011.649325. Epub 2012 Jan 6.

PMID:
22168788
5.

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Ollendorf DA, Klingman D, Hazard E, Ray S.

Clin Ther. 2009 Apr;31(4):825-35. doi: 10.1016/j.clinthera.2009.04.002.

PMID:
19446156
7.

A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.

Nuijten MJ, Engelfriet P, Duijn K, Bruijn G, Wierz D, Koopmanschap M.

Pharmacoeconomics. 2001;19(10):1051-64.

PMID:
11735673
8.

Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis.

Bullano MF, McNeeley BJ, Yu YF, Quimbo R, Burawski LP, Yu EB, Woolley JM.

Manag Care Interface. 2006 Sep;19(9):47-53.

PMID:
17017313
9.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

10.

Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.

Ollendorf DA, Peterson AN, Doyle J, Huse DM.

Am J Manag Care. 2002 May;8(7 Suppl):S203-13.

12.

Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.

Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM.

Adv Ther. 2012 Mar;29(3):234-48. doi: 10.1007/s12325-012-0007-y. Epub 2012 Mar 9.

PMID:
22411424
13.

Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.

Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, Klareskog L, Ulfgren AK.

Arthritis Rheum. 2005 Jan;52(1):61-72.

14.

Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study.

Schabert VF, Bruce B, Ferrufino CF, Globe DR, Harrison DJ, Lingala B, Fries JF.

Curr Med Res Opin. 2012 Apr;28(4):569-80. doi: 10.1185/03007995.2012.656844. Epub 2012 Mar 6.

PMID:
22236091
15.

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.

Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG, Frati E, Foschi V, Gasparini S, Giardina A, Gremese E, Iannone F, Sebastiani M, Ziglioli T, Biasi D, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Gorla R, Govoni M, Lapadula G, Marchesoni A, Salaffi F, Punzi L, Triolo G, Ferraccioli G.

Autoimmun Rev. 2012 Dec;12(2):225-9. doi: 10.1016/j.autrev.2012.06.008. Epub 2012 Jul 13.

PMID:
22796281
16.

Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis.

Harrison DJ, Huang X, Globe D.

Am J Health Syst Pharm. 2010 Aug;67(15):1281-7. doi: 10.2146/ajhp090487.

PMID:
20651319
17.
18.

Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.

Matsudaira R, Tamura N, Sekiya F, Ogasawara M, Yamanaka K, Takasaki Y.

J Rheumatol. 2011 Nov;38(11):2346-54. doi: 10.3899/jrheum.101295. Epub 2011 Oct 1.

PMID:
21965648
19.

Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.

Fernández-Nebro A, Irigoyen MV, Ureña I, Belmonte-López MA, Coret V, Jiménez-Núñez FG, Díaz-Cordovés G, López-Lasanta MA, Ponce A, Rodríguez-Pérez M, Calero E, González-Santos P.

J Rheumatol. 2007 Dec;34(12):2334-42. Epub 2007 Nov 1.

PMID:
17985409
20.

Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.

Ramírez-Herráiz E, Escudero-Vilaplana V, Alañón-Plaza E, Trovato-López N, Herranz-Alonso A, Morell-Baladrón A, Sanjurjo-Sáez M.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4):559-65. Epub 2013 May 27.

PMID:
23710583
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk